Literature DB >> 31092444

Usefulness of 18-FDG PET/CT in Detecting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Yo-Ichi Yamashita1, Hirohisa Okabe2, Hiromitsu Hayashi2, Katsunori Imai2, Shigeki Nakagawa2, Yosuke Nakao2, Toshihiko Yusa2, Rumi Itoyama2, Takanobu Yama2, Naoki Umesaki2, Kota Arima2, Tatsunori Miyata2, Akira Chikamoto2, Hideo Baba2.   

Abstract

BACKGROUND/AIM: Identifying malignancy in intraductal papillary mucinous neoplasm (IPMN) of the pancreas remains challenging. This study aimed to evaluate the usefulness of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18-FDG PET/CT) in distinguishing malignant from benign IPMN of the pancreas. PATIENTS AND METHODS: The cases of 79 patients with IPMN of the pancreas who underwent surgical resections between 1996 and 2016 at our Institution were enrolled in the present retrospective analysis of predictors for malignancy in IPMN of the pancreas. 18-FDG PET/CT evaluations were performed in 38 patients, and the usefulness of 18-FDG PET/CT for detecting malignancy in IPMN of the pancreas was evaluated.
RESULTS: Three factors were significantly related to malignancy in IPMN; the diameter of the main pancreatic duct, the serum value of carcinoembryonic antigen (CEA), and the neutrophil-to-lymphocyte ratio (NLR). 18-FDG PET accumulation was significantly related to malignancy in IPMN; sensitivity 0.82 and specificity 0.71. Independent predictors for malignancy in IPMN were as follows: 18-FDG PET accumulation, CEA >1.0 ng/ml, and NLR >2.63.
CONCLUSION: 18-FDG PET accumulation is a potent new marker for distinguishing malignant from benign IPMNs of the pancreas. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  18-FDG PET/CT; IPMCa; IPMN of the pancreas; neutrophil-to-lymphocyte ration (NLR); predictors

Mesh:

Substances:

Year:  2019        PMID: 31092444     DOI: 10.21873/anticanres.13369

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Pancreatic FDG uptake on follow-up PET/CT in patients with cancer.

Authors:  Hitomi Iwasa; Yoriko Murata; Miki Nishimori; Kana Miyatake; Shino Kohsaki; Naoya Hayashi; Naoki Akagi; Takuhiro Kohsaki; Kazushige Uchida; Takuji Yamagami
Journal:  Oncol Lett       Date:  2021-02-09       Impact factor: 2.967

2.  Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver.

Authors:  Jin Uk Choi; Shin Hwang; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jae Seung Kim; Seung-Mo Hong
Journal:  Ann Surg Treat Res       Date:  2022-06-07       Impact factor: 1.766

Review 3.  The Role of Positron Emission Tomography in Clinical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Simone Serafini; Cosimo Sperti; Alessandra Rosalba Brazzale; Diego Cecchin; Pietro Zucchetta; Elisa Sefora Pierobon; Alberto Ponzoni; Michele Valmasoni; Lucia Moletta
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

4.  Serum N-Glycome analysis reveals pancreatic cancer disease signatures.

Authors:  Gerda C M Vreeker; Randa G Hanna-Sawires; Yassene Mohammed; Marco R Bladergroen; Simone Nicolardi; Viktoria Dotz; Jan Nouta; Bert A Bonsing; Wilma E Mesker; Yuri E M van der Burgt; Manfred Wuhrer; Rob A E M Tollenaar
Journal:  Cancer Med       Date:  2020-09-08       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.